Ovalbumin (OVA) is a 45 kDa protein found in egg whites and is widely recognized as the gold-standard model antigen in immunology and vaccine development. Traditionally, researchers used OVA protein for immunization studies; however, the shift toward nucleic acid therapeutics has made OVA messenger RNA (mRNA) an essential tool for studying antigen presentation, T-cell activation, and vaccine delivery efficiency. Unlike protein-based models, mRNA-encoded OVA allows for the endogenous production of the antigen within the host cell, more closely mimicking the natural infection process and facilitating robust major histocompatibility complex (MHC) class I and II presentation.
At CD BioGlyco, we provide a specialized OVA mRNA synthesis service designed to support high-end research in immunotherapy and gene delivery. Our synthesized OVA mRNA mimics fully matured cellular mRNA, featuring a 5' cap, a 3' polyadenylated [poly(A)] tail, and optimized untranslated regions (UTRs) to maximize translation efficiency and stability. Whether your project requires unmodified mRNA or chemically modified variants to evade innate immune recognition, our platform delivers the precision and purity necessary for reproducible scientific breakthroughs.
We utilize high-fidelity T7 RNA polymerase systems to transcribe DNA templates into high-quality mRNA. This cell-free production system eliminates the risk of genomic integration and toxic cellular byproducts associated with traditional plasmid-based delivery.
To reduce the activation of pattern recognition receptors (PRRs) like Toll-like receptors (TLRs), we offer the incorporation of modified nucleotides such as N1-methylpseudouridine (N1-mψ) or 5-methoxyuridine (5moU). These modifications significantly enhance protein yield by increasing mRNA stability and translation capacity.
We employ co-transcriptional capping technologies (e.g., Cap 1 structures) and enzymatic polyadenylation to produce mRNA with high capping efficiency (typically >95%). This ensures the mRNA is recognized by the ribosome as endogenous, protecting it from 5' exonuclease degradation.
As a critical component of our Therapeutic Nucleic Acid Development Platform, the OVA mRNA synthesis service at CD BioGlyco is integrated within our specialized Therapeutic Oligonucleotide Synthesis Service. We provide a comprehensive range of synthesis options to meet various research scales and complexity levels:
The process begins with the optimization of the OVA coding sequence. We adjust the codon usage to match the tRNA abundance of the target organism, while simultaneously removing cryptic splice sites and secondary structures that might hinder ribosome movement.
The optimized sequence is cloned into a specialized IVT vector. After sequence verification via Sanger sequencing, the circular plasmid is linearized using high-fidelity restriction enzymes to create a precise template for the T7 RNA polymerase, ensuring a defined 3' end.
Using the linearized DNA as a template, we perform a highly controlled IVT reaction. During this stage, we incorporate either standard or modified nucleoside triphosphates (NTPs) according to the project specifications to ensure the desired biological activity.
To mimic mature eukaryotic mRNA, we apply a 5' Cap 1 structure and a long poly(A) tail (typically 100-120 nucleotides). This step is crucial for protecting the transcript from degradation and ensuring high binding affinity to the translation initiation complex.
Raw mRNA is subjected to rigorous purification using tangential flow filtration (TFF) or high-performance liquid chromatography (HPLC). This removes residual DNA templates, enzymes, and, most importantly, double-stranded RNA (dsRNA) contaminants that could trigger unintended immune responses.
Every batch undergoes a comprehensive QC battery, including bioanalyzer analysis for integrity, fragment analyzer for length verification, and slot-blot assays for dsRNA quantification.
Vaccine Development
OVA mRNA serves as a model antigen for evaluating the efficacy of novel vaccine platforms, allowing researchers to measure specific CD8+ and CD4+ T-cell responses and antibody titers in mouse models.
Drug Delivery System (DDS) Testing
It is the standard cargo for testing the transfection efficiency and biodistribution of lipid nanoparticles (LNPs), polymers, and other delivery vehicles across different tissues and administration routes.
Cancer Immunotherapy Research
Researchers use OVA-expressing mRNA to study the mechanisms of tumor-associated antigen presentation and the effectiveness of chimeric antigen receptor (CAR) T-cell or dendritic cell-based therapies in B16-OVA tumor models.
Antigen Presentation Studies
Our mRNA is used to investigate the kinetics of MHC class I cross-presentation in professional antigen-presenting cells (APCs), providing insights into how different modifications affect the speed and duration of protein expression.
Exceptional Purity Levels
Our advanced purification protocols effectively remove dsRNA and other impurities, ensuring that the biological effects observed in your study are due to the OVA antigen and not unintended inflammatory artifacts.
Customizable Nucleoside Modifications
We offer a versatile selection of modified nucleotides, including N1-methylpseudouridine, which has been shown to significantly increase protein expression and stability in various mammalian cell lines and animal models.
Optimized Capping Efficiency
Utilizing the latest co-transcriptional capping technology, we consistently achieve capping efficiencies exceeding 95%, leading to higher translation rates and superior experimental reproducibility across different laboratories and batches.
Comprehensive Quality Assurance
Every order is accompanied by a detailed certificate of analysis (COA) covering mRNA integrity, purity, concentration, and endotoxin levels, providing you with full confidence in your experimental materials.
"The N1-methylpseudouridine-modified OVA mRNA from CD BioGlyco showed significantly higher expression in our dendritic cell cultures compared to our previous supplier. The low endotoxin levels were critical for our T-cell activation assays."
– R.S., Principal Investigator
"We used their OVA mRNA service for a large-scale LNP delivery study. The batch-to-batch consistency was impressive, and the technical support helped us optimize the poly(A) tail length for our specific model."
– A.S., Senior Scientist
"Fast turnaround and excellent purity. The fragment analyzer data provided in the COA matched our internal QC perfectly. This is now our go-to source for model antigen mRNA."
– B.R., Postdoctoral Fellow
CD BioGlyco provides a premier OVA mRNA synthesis service, leveraging cutting-edge IVT technology and rigorous purification to deliver high-performance model antigens. Our commitment to quality, scalability, and technical expertise makes us the ideal partner for your next immunology or vaccine project. Please feel free to contact us to discuss your sequence design, scale requirements, and delivery strategies.
